Abstract
Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 2310-2312 |
| Number of pages | 3 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 39 |
| Issue number | 12 |
| Publication status | Published - 2012 Nov |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
